Sodium channel epithelial 1 subunit alpha (SCNN1A) mRNA (SCNN1A mRNA)

Sodium channel epithelial 1 subunit alpha (SCNN1A) mRNA is the transcript encoding the alpha subunit of the epithelial sodium channel (ENaC), a heteromeric protein complex that mediates the rate-limiting step of sodium reabsorption across epithelial membranes (UniProt P37088). In the respiratory system, SCNN1A-mediated sodium transport is a primary determinant of airway surface liquid (ASL) volume; overactivity of this channel leads to ASL dehydration, resulting in thick mucus and impaired mucociliary clearance, which are central to the pathogenesis of cystic fibrosis and bronchiectasis (PubMed: 29439140). In the kidneys, the encoded protein is essential for maintaining salt-water balance and systemic blood pressure, with gain-of-function mutations causing Liddle syndrome, a form of severe hypertension (NIH: GeneID 6337). While traditional therapies like amiloride target the ENaC protein directly, modern drug development focuses on SCNN1A mRNA using antisense oligonucleotides (ASOs) to reduce the overall production of the channel subunits (ClinicalTrials.gov: NCT03647358). This mRNA-targeting approach aims to provide a more sustained reduction in sodium absorption in the lungs compared to short-acting small molecule inhibitors. However, therapeutic modulation of SCNN1A requires careful monitoring of potassium levels, as systemic inhibition can lead to life-threatening hyperkalemia.

Other names

Alpha-ENaC mRNAENaC-alpha mRNAAmiloride-sensitive sodium channel subunit alpha transcriptSCNN1 mRNANon-voltage-gated sodium channel 1 subunit alpha mRNA

Antisense-mediated degradation of SCNN1A mRNA to reduce protein expression or direct inhibition of the encoded epithelial sodium channel (ENaC) to decrease sodium reabsorption.